Real Time Insider Transaction Data
Real Time Insider buys and sells Data - Insider Trades - Insider Transactions - Insider Trading Data - SEC Form 4 Data
Total | Transactions | Amount |
Buys | 0 | $0 |
Sells | 37 | $1,081,499 |
Security | Reporting Name | Relationship | Purchase/Sale | Shares | Price $ | D/I | ||||
20 Jun 2024 16:58 | NRIX | Nurix Therapeutics Inc | VAN HOUTE HANS | Chief Financial Officer | 20 Jun 2024 | Sale | 20,000 | 20.0108 | 400,216 | D |
13 Jun 2024 18:39 | NRIX | Nurix Therapeutics Inc | RING CHRISTINE | Chief Legal Officer | 13 Jun 2024 | Sale | 1,864 | 17.0178 | 31,721 | D |
12 Jun 2024 19:30 | NRIX | Nurix Therapeutics Inc | RING CHRISTINE | Chief Legal Officer | 12 Jun 2024 | Sale | 1,900 | 17.01 | 32,319 | D |
05 Jun 2024 18:01 | NRIX | Nurix Therapeutics Inc | RING CHRISTINE | Chief Legal Officer | 05 Jun 2024 | Sale | 400 | 17.0025 | 6,801 | D |
03 Jun 2024 18:36 | NRIX | Nurix Therapeutics Inc | RING CHRISTINE | Chief Legal Officer | 03 Jun 2024 | Sale | 1,596 | 17.0131 | 27,153 | D |
02 May 2024 18:01 | NRIX | Nurix Therapeutics Inc | VAN HOUTE HANS | Chief Financial Officer | 02 May 2024 | Sale | 3,499 | 12.826 | 44,878 | D |
30 Apr 2024 18:33 | NRIX | Nurix Therapeutics Inc | VAN HOUTE HANS | Chief Financial Officer | 30 Apr 2024 | Sale | 1,387 | 12.0422 | 16,703 | D |
30 Apr 2024 18:33 | NRIX | Nurix Therapeutics Inc | HANSEN GWENN | Chief Scientific Officer | 30 Apr 2024 | Sale | 2,007 | 12.0422 | 24,169 | D |
30 Apr 2024 18:33 | NRIX | Nurix Therapeutics Inc | RING CHRISTINE | Chief Legal Officer | 30 Apr 2024 | Sale | 1,513 | 12.0422 | 18,220 | D |
16 Feb 2024 19:20 | NRIX | Nurix Therapeutics Inc | VAN HOUTE HANS | Chief Financial Officer | 16 Feb 2024 | Sale | 6,812 | 10.0151 | 68,223 | D |
30 Jan 2024 18:53 | NRIX | Nurix Therapeutics Inc | VAN HOUTE HANS | Chief Financial Officer | 30 Jan 2024 | Sale | 1,671 | 7.9902 | 13,352 | D |
30 Jan 2024 18:52 | NRIX | Nurix Therapeutics Inc | HANSEN GWENN | Chief Scientific Officer | 30 Jan 2024 | Sale | 2,334 | 7.9902 | 18,649 | D |
30 Jan 2024 18:52 | NRIX | Nurix Therapeutics Inc | RING CHRISTINE | Chief Legal Officer | 30 Jan 2024 | Sale | 1,760 | 7.9902 | 14,063 | D |
21 Dec 2023 17:19 | NRIX | Nurix Therapeutics Inc | VAN HOUTE HANS | Chief Financial Officer | 20 Dec 2023 | Sale | 3,541 | 10.0031 | 35,421 | D |
20 Dec 2023 16:55 | NRIX | Nurix Therapeutics Inc | VAN HOUTE HANS | Chief Financial Officer | 19 Dec 2023 | Sale | 10,906 | 10.003 | 109,093 | D |
01 Nov 2023 16:41 | NRIX | Nurix Therapeutics Inc | VAN HOUTE HANS | Chief Financial Officer | 31 Oct 2023 | Sale | 1,080 | 5.1974 | 5,613 | D |
01 Nov 2023 16:40 | NRIX | Nurix Therapeutics Inc | RING CHRISTINE | Chief Legal Officer | 31 Oct 2023 | Sale | 1,232 | 5.1974 | 6,403 | D |
01 Nov 2023 16:40 | NRIX | Nurix Therapeutics Inc | HANSEN GWENN | Chief Scientific Officer | 31 Oct 2023 | Sale | 1,633 | 5.1974 | 8,487 | D |
01 Aug 2023 16:28 | NRIX | Nurix Therapeutics Inc | VAN HOUTE HANS | Chief Financial Officer | 31 Jul 2023 | Sale | 1,245 | 9.6547 | 12,020 | D |
01 Aug 2023 16:27 | NRIX | Nurix Therapeutics Inc | RING CHRISTINE | General Counsel | 31 Jul 2023 | Sale | 1,420 | 9.6547 | 13,710 | D |
01 Aug 2023 16:26 | NRIX | Nurix Therapeutics Inc | HANSEN GWENN | Chief Scientific Officer | 31 Jul 2023 | Sale | 1,884 | 9.6547 | 18,189 | D |
02 May 2023 16:33 | NRIX | Nurix Therapeutics Inc | WOLFF STEFANI | EVP and COO | 01 May 2023 | Sale | 342 | 9.8763 | 3,378 | D |
02 May 2023 16:33 | NRIX | Nurix Therapeutics Inc | VAN HOUTE HANS | Chief Financial Officer | 01 May 2023 | Sale | 721 | 9.8763 | 7,121 | D |
02 May 2023 16:32 | NRIX | Nurix Therapeutics Inc | RING CHRISTINE | General Counsel | 01 May 2023 | Sale | 682 | 9.8763 | 6,736 | D |
02 May 2023 16:31 | NRIX | Nurix Therapeutics Inc | HANSEN GWENN | Chief Scientific Officer | 01 May 2023 | Sale | 1,136 | 9.8763 | 11,219 | D |
01 Feb 2023 16:18 | NRIX | Nurix Therapeutics Inc | WOLFF STEFANI | EVP and COO | 30 Jan 2023 | Sale | 424 | 11.7796 | 4,995 | D |
01 Feb 2023 16:17 | NRIX | Nurix Therapeutics Inc | VAN HOUTE HANS | Chief Financial Officer | 30 Jan 2023 | Sale | 924 | 11.7796 | 10,884 | D |
01 Feb 2023 16:16 | NRIX | Nurix Therapeutics Inc | RING CHRISTINE | General Counsel | 30 Jan 2023 | Sale | 848 | 11.7796 | 9,989 | D |
01 Feb 2023 16:15 | NRIX | Nurix Therapeutics Inc | HANSEN GWENN | Chief Scientific Officer | 30 Jan 2023 | Sale | 1,412 | 11.7796 | 16,633 | D |
01 Nov 2022 19:35 | NRIX | Nurix Therapeutics Inc | VAN HOUTE HANS | Chief Financial Officer | 31 Oct 2022 | Sale | 739 | 12.8805 | 9,519 | D |
01 Nov 2022 19:34 | NRIX | Nurix Therapeutics Inc | RING CHRISTINE | General Counsel | 31 Oct 2022 | Sale | 699 | 12.8805 | 9,003 | D |
01 Nov 2022 19:33 | NRIX | Nurix Therapeutics Inc | HANSEN GWENN | Chief Scientific Officer | 31 Oct 2022 | Sale | 1,165 | 12.8805 | 15,006 | D |
01 Nov 2022 19:32 | NRIX | Nurix Therapeutics Inc | WOLFF STEFANI | EVP and COO | 31 Oct 2022 | Sale | 350 | 12.8805 | 4,508 | D |
02 Aug 2022 17:50 | NRIX | Nurix Therapeutics Inc | RING CHRISTINE | General Counsel | 01 Aug 2022 | Sale | 712 | 15.67 | 11,157 | D |
02 Aug 2022 17:48 | NRIX | Nurix Therapeutics Inc | WOLFF STEFANI | EVP and COO | 01 Aug 2022 | Sale | 356 | 15.67 | 5,579 | D |
02 Aug 2022 17:46 | NRIX | Nurix Therapeutics Inc | VAN HOUTE HANS | Chief Financial Officer | 01 Aug 2022 | Sale | 752 | 15.67 | 11,784 | D |
02 Aug 2022 17:45 | NRIX | Nurix Therapeutics Inc | HANSEN GWENN | Chief Scientific Officer | 01 Aug 2022 | Sale | 1,186 | 15.67 | 18,585 | D |
* D/I = Direct / Indirect
* 10% = Entity with 10% or higher ownership stake
* A = Amendment Filing (SEC Form 4/A)